Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response. (1st January 2021)
- Record Type:
- Journal Article
- Title:
- Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response. (1st January 2021)
- Main Title:
- Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response
- Authors:
- Raynaud, Adeline
Desrumeaux, Klervi
Vidard, Laurent
Termine, Elise
Baty, Daniel
Chames, Patrick
Vigne, Emmanuelle
Kerfelec, Brigitte - Abstract:
- ABSTRACT: The natural killer group 2 member D (NKG2D) receptor is a C-type lectin-like activating receptor mainly expressed by cytotoxic immune cells including NK, CD8 + T, γδ T and NKT cells and in some pathological conditions by a subset of CD4 + T cells. It binds a variety of ligands (NKG2DL) whose expressions is finely regulated by stress-related conditions. The NKG2DL/NKG2D axis plays a central and complex role in the regulation of immune responses against diverse cellular threats such as oncogene-mediated transformations or infections. We generated a panel of seven highly specific anti-human NKG2D single-domain antibodies targeting various epitopes. These single-domain antibodies were integrated into bivalent and bispecific antibodies using a versatile plug-and-play Fab-like format. Depending on the context, these Fab-like antibodies exhibited activating or inhibitory effects on the immune response mediated by the NKG2DL/NKG2D axis. In solution, the bivalent anti-NKG2D antibodies that compete with NKG2DL potently blocked the activation of NK cells seeded on immobilized MICA, thus constituting antagonizing candidates. Bispecific anti-NKG2DxHER2 antibodies that concomitantly engage HER2 on tumor cells and NKG2D on NK cells elicited cytotoxicity of unstimulated NK in a tumor-specific manner, regardless of their apparent affinities and epitopes. Importantly, the bispecific antibodies that do not compete with ligands binding retained their full cytotoxic activity in theABSTRACT: The natural killer group 2 member D (NKG2D) receptor is a C-type lectin-like activating receptor mainly expressed by cytotoxic immune cells including NK, CD8 + T, γδ T and NKT cells and in some pathological conditions by a subset of CD4 + T cells. It binds a variety of ligands (NKG2DL) whose expressions is finely regulated by stress-related conditions. The NKG2DL/NKG2D axis plays a central and complex role in the regulation of immune responses against diverse cellular threats such as oncogene-mediated transformations or infections. We generated a panel of seven highly specific anti-human NKG2D single-domain antibodies targeting various epitopes. These single-domain antibodies were integrated into bivalent and bispecific antibodies using a versatile plug-and-play Fab-like format. Depending on the context, these Fab-like antibodies exhibited activating or inhibitory effects on the immune response mediated by the NKG2DL/NKG2D axis. In solution, the bivalent anti-NKG2D antibodies that compete with NKG2DL potently blocked the activation of NK cells seeded on immobilized MICA, thus constituting antagonizing candidates. Bispecific anti-NKG2DxHER2 antibodies that concomitantly engage HER2 on tumor cells and NKG2D on NK cells elicited cytotoxicity of unstimulated NK in a tumor-specific manner, regardless of their apparent affinities and epitopes. Importantly, the bispecific antibodies that do not compete with ligands binding retained their full cytotoxic activity in the presence of ligands, a valuable property to circumvent immunosuppressive effects induced by soluble ligands in the microenvironment. … (more)
- Is Part Of:
- Oncoimmunology. Volume 10:Number 1(2021)
- Journal:
- Oncoimmunology
- Issue:
- Volume 10:Number 1(2021)
- Issue Display:
- Volume 10, Issue 1 (2021)
- Year:
- 2021
- Volume:
- 10
- Issue:
- 1
- Issue Sort Value:
- 2021-0010-0001-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-01-01
- Subjects:
- NKG2D/NKG2DL axis -- NK cells -- HER2 -- single-domain antibody -- cell engagers
Tumors -- Immunological aspects -- Periodicals
Neoplasms -- therapy -- Periodicals
Immunotherapy -- Periodicals
616.994 - Journal URLs:
- http://www.landesbioscience.com/journals/oncoimmunology/ ↗
http://www.tandfonline.com/toc/koni20/current ↗
http://www.tandf.co.uk/journals/ ↗ - DOI:
- 10.1080/2162402X.2020.1854529 ↗
- Languages:
- English
- ISSNs:
- 2162-402X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25397.xml